Coronado Biosciences, Inc. (NASDAQ: CNDO) said that it expects data from its Phase 2 trials of Trichuris suis ova suspension (TSO) in patients with Crohn’s disease, during 2H 2013. Orexigen Therapeutics, Inc. (Nasdaq: OREX) maintained guidance that it expects to conduct the interim analysis from the Light Study and resubmit the Contrave NDA in 2013. However, as the company stated […]
Archive for Charts
Chart by @VexTrades - Upcoming Events PDUFA date February 17, 2012 for Korlym (CORLUX) for the treatment of the manifestations of Cushing’s Syndrome. Click on chart to enlarge, then click on “expand” icon at top right for a clearer image.
Chart by @VexTrades - EDIT 12/15/11 – This chart is of little significance since following the posting BPAX released data showing it had failed its Phase 3 efficacy trials. Upcoming Events Phase 3 efficacy data of Libigel for Female sexual dysfunction due 4Q 2011. Stock does tend to sell off following the release of data so trade wisely! […]
By @VexTrades - Upcoming Events December 2011 - Top-line results due from its retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy or FORTRESS, in the offspring of women who were exposed to topiramate during the first trimester of pregnancy. Data will be used as part of the QNEXA NDA resubmission […]
By @VexTrades – Upcoming Events Phase 3 efficacy data of Libigel for Female sexual dysfunction due 4Q 2011. Safety data due 3Q 2012 and NDA filing due 4Q 2012. PDUFA 2/14/12 of Bio-T-Gel for male hypogonadism partnered with TEVA. Click on chart to enlarge, then click on “expand” icon at top right for a clearer […]